Ecrins Therapeutics Competitors and Similar CompaniesClear all

Ecrins Therapeutics's competitors and similar companies include Fluxion Biosciences, Adimab, Telix Pharmaceuticals and Adagene.

	Ecrins Therapeutics Ecrins Therapeutics is a biotechnology company that focuses on the discovery and development of anti-cancer compounds.	Fluxion Biosciences Fluxion Biosciences is a company developing systems for live cell analysis.	Adimab Adimab is a biotechnology company that provides a discovery platform functioning as a synthetic human immune system.	Telix Pharmaceuticals Telix Pharmaceuticals is a company developing molecularly targeted radiation products for cancer care.	Adagene Adagene is an antibody discovery and development biotechnology company specializing in oncology immunotherapy.
Founding Date	Founding Date 2010	Founding Date 2005	Founding Date 2007	Founding Date 2015	Founding Date 2012
Type	Type Private	Type Private	Type Private	Type Public	Type Public
Tags	Tags Healthcare biotech clinical research drug development oncology	Tags Healthcare biotech clinical research drug development oncology	Tags Healthcare biotech clinical research drug development life sciences oncology	Tags Healthcare biotech clinical research drug development oncology pharma	Tags Healthcare biotech clinical research drug development oncology therapy
Locations	Locations La Tronche, FR HQ	Locations Alameda, US HQ	Locations Lebanon, US HQ	Locations North Melbourne, AU HQ Milton, AU Sydney, AU Herstal, BE Burnaby, CA Kyoto, JP Lancy, CH see more	Locations Suzhou, CN HQ San Diego, US San Francisco, US
Employees	Employees 1	Employees 7	Employees 1384% increase	Employees 415	Employees 13821% decrease
Valuation ($)	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 4.6 b	Valuation ($) 137.2 m
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) $803.8m (FY, 2025)	Revenue (est.) $7.7m (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A	Cost of goods $356m (FY, 2025)	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit N/A	Gross profit $449m (FY, 2025)	Gross profit $7.7m (FY, 2025)
Net income	Net income N/A	Net income N/A	Net income N/A	Net income ($7.1m) (FY, 2025)	Net income ($17.6m) (FY, 2025)
Funding
Latest funding round	Latest funding round $ 599.1k (almost 11 years ago)	Latest funding round $ 280k (over 6 years ago)	Latest funding round N/A	Latest funding round N/A	Latest funding round N/A
Total funding raised	Total funding raised $ 2.7m	Total funding raised $ 22.5m	Total funding raised $ 45.3m	Total funding raised N/A	Total funding raised $ 155m